Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.732
Abstract: Revefenacin is a novel once‐daily, lung‐selective, long‐acting muscarinic antagonist developed as a nebulized inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease. In a randomized, 4‐way crossover study, healthy subjects received a single… read more here.
Keywords: muscarinic antagonist; long acting; prolong interval; healthy subjects ... See more keywords
Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
Sign Up to like & getrecommendations! Published in 2018 at "BioMed Research International"
DOI: 10.1155/2018/7473690
Abstract: Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient's severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled… read more here.
Keywords: antagonist tiotropium; muscarinic antagonist; long acting; tiotropium ... See more keywords